Why the study?
Does the AT1R 1166 C allele increase the risk of hypertrophic cardiomyopathy in patients without sarcomeric mutations?
Does the AT1R 1166 C allele increase the risk of hypertrophic cardiomyopathy in patients without sarcomeric mutations?
Answers are grounded in this paper and cite their sources.
The AT1R 1166 C allele may serve as a genetic risk modifier for cardiac hypertrophy and increased left ventricular wall thickness in patients lacking sarcomeric mutations.
BACKGROUND: Angiotensin and serotonin have been identified as inducers of cardiac hypertrophy. DNA polymorphisms at the genes encoding components of the angiotensin and serotonin systems have been associated with the risk of developing cardiovascular diseases, including left ventricular hypertrophy (LVH). METHODS: We genotyped five polymorphisms of the AGT, ACE, AT1R, 5-HT2A, and 5-HTT genes in 245 patients with Hypertrophic Cardiomyopathy (HCM; 205 without an identified sarcomeric gene mutation), in 145 patients with LVH secondary to hypertension, and 300 healthy controls. RESULTS: We found a significantly higher frequency of AT1R 1166 C carriers (CC+AC) among the HCM patients without sarcomeric mutations compared to controls (p = 0.015; OR = 1.56; 95%CI = 1.09-2.23). The AT1R 1166 C was also more frequent among patients who had at least one affected relative, compared to sporadic cases. This allele was also associated with higher left ventricular wall thickness in both, HCM patients with and without sarcomeric mutations. CONCLUSIONS: The 1166 C AT1R allele could be a risk factor for cardiac hypertrophy in patients without sarcomeric mutations. Other variants at the AGT, ACE, 5-HT2A and 5-HTT did not contribute to the risk of cardiac hypertrophy.
No takes yet. Share an insight, caveat, or question.
Coto et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: